Harbour BioMed, a global biopharmaceutical company focused on advancing innovative antibody-based therapies in immunology and immune-oncology, has announced the online publication of results from the first-in-human Phase I clinical trial …
Foresee Pharmaceuticals has announced that the independent Data and Safety Monitoring Board (DSMB) has completed its fourth safety review of the Casppian Phase 3 registration study and reported positive findings. …
